But all that being said, I do not know the content of these conversations and so am only speculating on the potential ethics of the complicated situation
The GIP arm is what differentiates it from semaglutide: GIP co-agonism amplifies glucose-dependent insulin secretion and, in preclinical and early clinical models, appears to blunt the nausea signal that GLP-1 mono-agonists generate at higher titration steps
Therefore, PS exposure, a characteristic of suicidal erythrocyte death or eryptosis, accelerates the clearance of affected erythrocytes from the circulating blood
It wasn't a magic bullet, but it felt like a helpful nudge in the right direction
I believe that the notion of oral GLP-1s being a net negative for Stevanato is pretty misguided, for several reasons
Her is one retailer that has managed to meet all of our expectations